1. Home
  2. NAD vs ARQT Comparison

NAD vs ARQT Comparison

Compare NAD & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAD
  • ARQT
  • Stock Information
  • Founded
  • NAD 1999
  • ARQT 2016
  • Country
  • NAD United States
  • ARQT United States
  • Employees
  • NAD N/A
  • ARQT N/A
  • Industry
  • NAD Investment Managers
  • ARQT Biotechnology: Pharmaceutical Preparations
  • Sector
  • NAD Finance
  • ARQT Health Care
  • Exchange
  • NAD Nasdaq
  • ARQT Nasdaq
  • Market Cap
  • NAD 2.8B
  • ARQT 3.3B
  • IPO Year
  • NAD N/A
  • ARQT 2020
  • Fundamental
  • Price
  • NAD $11.98
  • ARQT $30.97
  • Analyst Decision
  • NAD
  • ARQT Strong Buy
  • Analyst Count
  • NAD 0
  • ARQT 7
  • Target Price
  • NAD N/A
  • ARQT $22.17
  • AVG Volume (30 Days)
  • NAD 595.7K
  • ARQT 2.7M
  • Earning Date
  • NAD 01-01-0001
  • ARQT 10-28-2025
  • Dividend Yield
  • NAD 4.35%
  • ARQT N/A
  • EPS Growth
  • NAD N/A
  • ARQT N/A
  • EPS
  • NAD N/A
  • ARQT N/A
  • Revenue
  • NAD N/A
  • ARQT $317,929,000.00
  • Revenue This Year
  • NAD N/A
  • ARQT $85.27
  • Revenue Next Year
  • NAD N/A
  • ARQT $30.70
  • P/E Ratio
  • NAD N/A
  • ARQT N/A
  • Revenue Growth
  • NAD N/A
  • ARQT 129.21
  • 52 Week Low
  • NAD $9.56
  • ARQT $10.57
  • 52 Week High
  • NAD $11.64
  • ARQT $31.11
  • Technical
  • Relative Strength Index (RSI)
  • NAD 55.98
  • ARQT 75.88
  • Support Level
  • NAD $11.89
  • ARQT $27.08
  • Resistance Level
  • NAD $12.03
  • ARQT $31.10
  • Average True Range (ATR)
  • NAD 0.09
  • ARQT 1.59
  • MACD
  • NAD -0.01
  • ARQT 0.50
  • Stochastic Oscillator
  • NAD 52.70
  • ARQT 98.36

About NAD Nuveen Quality Municipal Income Fund

Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: